Stock comparison
IDEXX Laboratories
Novo Nordisk A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
NVO
Novo Nordisk A/S
Market cap
$199.21B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | NVO | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 65B | IDXX |
| Benjamin Graham | 80A | 61C | IDXX |
| Philip Fisher | 75B | 73B | IDXX |
| Peter Lynch | 71B | 57C | IDXX |
| Joel Greenblatt | 83C | 56C | IDXX |
| Charlie Munger | 87A | 76B | IDXX |
| Terry Smith | 84A | 72C | IDXX |
Side-by-side metrics
| Metric | IDXX | NVO |
|---|---|---|
| Market cap | $44.06B | $199.21B |
| P/E (TTM) | 39.0x | 10.4x |
| EV/EBIT | 31.6x | 10.9x |
| ROIC (TTM) | 40.66% | 32.2% |
| Gross margin | 62.05% | 81.85% |
| Net margin | 24.63% | 37.2% |
| Revenue CAGR 5y | 7.56% | 21.72% |
| EPS CAGR 5y | 10.79% | 22.03% |
| Debt / Equity | 0.7x | 0.7x |
| Dividend yield | 0.0% | 4.09% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 32.2%+21%
NVO leads on
- Dividend yield4.09%vs 0.0%+100%
- Market cap$199.21Bvs $44.06B+78%
- P/E (TTM)10.4xvs 39.0x+73%
- EV/EBIT10.9xvs 31.6x+65%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.